The objective of this study was to compare the efficacy and safety of dacarbazine (DTIC) with or without placebo and DTIC–based combination therapies in patients with advanced metastatic melanoma. These data suggested that DTIC–based combination therapies could moderately improve the overall response and the 1–year survival but increased the incidence of adverse events.

READ FULL ARTICLE Curated publisher From Mdlinx